256 related articles for article (PubMed ID: 16608106)
1. [The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis].
Demina TL; Khachanova NV; Davydovskaia MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(3):15-9. PubMed ID: 16608106
[TBL] [Abstract][Full Text] [Related]
2. The importance of early diagnosis of multiple sclerosis.
Miller JR
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S4-11. PubMed ID: 15253684
[TBL] [Abstract][Full Text] [Related]
3. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
4. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
Goodin DS; Bates D
Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
[TBL] [Abstract][Full Text] [Related]
5. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
6. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE
Mult Scler; 2011 Mar; 17(3):353-60. PubMed ID: 20965959
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
8. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
[TBL] [Abstract][Full Text] [Related]
9. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
11. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
12. [Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?].
Vermersch P
Presse Med; 2004 Feb; 33(3):180-6; discussion 192. PubMed ID: 15029033
[TBL] [Abstract][Full Text] [Related]
13. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response.
Coyle PK; Hartung HP
Mult Scler; 2002 Feb; 8(1):2-9. PubMed ID: 11936484
[TBL] [Abstract][Full Text] [Related]
14. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis].
Waubant E; Sloan R; Andersson PB; Goodkin D
Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321
[TBL] [Abstract][Full Text] [Related]
15. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.
Zivadinov R; Munschauer FE; Ramanathan M; Benedict RH; Weinstock-Guttman B
Drugs Today (Barc); 2008 Aug; 44(8):601-13. PubMed ID: 18846271
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
[TBL] [Abstract][Full Text] [Related]
18. Early treatment.
Comi G
Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
20. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
